Ministry of Health
Baghdad, 964, Iraq
NCT Number: NCT05193877
We present a randomized controlled trial (RCT) to assess the efficacy of autologous bone marrow aspirate concentrate BMAC of 1.8x 10 9 median cellular content in the treatment of early symptomatic knee OA. We use 2 injections 2 months apart (8).
Looking for future studies?
Notify Me55 year–85 year
All sexes
Interventional
Not applicable
Baghdad, 964, Iraq
A randomized controlled trial will be held in Ibn-Sina training hospital in Baghdad. All participants will complete written informed consent. The study will be a single centered trial.
The trial design will consist of 60 participant randomly and equally allocated to control and treatment group by simple random sampling. Participants will not be blinded to their treatment allocation. Control group will receive conventional treatment only. Intervention group will receive (2 injections) intra-articular injections of (4cc) per joint at (8 weeks' interval).
Intervention:
50 cc bone marrow aspirates concentrate after centrifugation with final volume up to 7 cc.
Assess total nucleated count and viability. Bone marrow aspirate concentrate is chosen as a source of mesenchymal stem cells, because of safe and easy procedure.
Bone marrow aspiration is done under local or general anesthesia, depending on the individual case. Around 50 cc of bone marrow is aspirated from the posterior iliac crest after proper sterilization using bone marrow aspiration needle (size according to the patient) and collected in heparinized syringes. Mononuclear cells (MNCs) are obtained by centrifugation. The isolated MNCs are checked for viability manually and confirmed on automated cell count machine.
The separated MNCs is administered intra-articularly immediately after centrifugation.
Place:
Bone marrow aspiration and centrifugation procedure is done in clean area, in operation room HEPA filtered with all instruments included. Cell count viability and flow cytometry can be sent to nearby lab.CD markers (90, 44,29,105,34).
Instruments:
Bone marrow aspiration kit, centrifuge, automated cell counter.
Sample size and sampling technique:
The conventional treatment is usually classic treatment .
Statistical analysis:
Raw data will be summarized, and presented in appropriate table. The statistical analysis will be carried out using SPSS (statistical package for social science) software version 25
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
50 cc bone marrow aspirates concentrate after centrifugation with final volume up to 7 cc.
Assess total nucleated count and viability. Bone marrow aspirate concentrate is chosen as a source of mesenchymal stem cells, because of safe and easy procedure.
Bone marrow aspiration is done under local or general anesthesia, depending on the individual case. Around 50 cc of bone marrow is aspirated from the posterior iliac crest after proper sterilization using bone marrow aspiration needle (size according to the patient) and collected in heparinized syringes. Mononuclear cells (MNCs) are obtained by centrifugation. The isolated MNCs are checked for viability manually and confirmed on automated cell count machine.
The separated MNCs is administered intra-articularly immediately after centrifugation.
Time frame: 6 months
improvement in pain scale WOMAC
Time frame: 6 months-1 year
MRI of the knee joint to monitor effect
Global Stem Cell Center, Baghdad
Industry
Autologous Bone Marrow Aspirate Concentrate Injection for the Treatment of Early Osteoarthritis: a Randomized Controlled Trial, Ibn-Sina Hospital, Baghdad 2022
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06768086
Behavior, Connective Tissue Diseases
Scorrano, Lecce, Italy
View Trial DetailsNCT04653818
Adenocarcinoma, Blood-Borne Infections
Alexandria, Egypt
View Trial DetailsNCT04824066
Recovery, Treatment Complication
Boston, Massachusetts, United States
View Trial DetailsNCT06152198
Arthroplasty Complications, Femoral Fractures
Uppsala, Sweden
View Trial Details